

agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 12:09:54 ON 22 FEB 2007

=> file registry

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 12:10:22 ON 22 FEB 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 20 FEB 2007 HIGHEST RN 922340-56-5

DICTIONARY FILE UPDATES: 20 FEB 2007 HIGHEST RN 922340-56-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006


Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10700909 formula 2 (ezetimibe).str



Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTACKH1617

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	OCT 23	The Derwent World Patents Index suite of databases on STN has been enhanced and reloaded
NEWS	4	OCT 30	CHEMLIST enhanced with new search and display field
NEWS	5	NOV 03	JAPIO enhanced with IPC 8 features and functionality
NEWS	6	NOV 10	CA/Capplus F-Term thesaurus enhanced
NEWS	7	NOV 10	STN Express with Discover! free maintenance release Version 8.01c now available
NEWS	8	NOV 20	CA/Capplus to MARPAT accession number crossover limit increased to 50,000
NEWS	9	DEC 01	CAS REGISTRY updated with new ambiguity codes
NEWS	10	DEC 11	CAS REGISTRY chemical nomenclature enhanced
NEWS	11	DEC 14	WPIDS/WPINDEX/WPIX manual codes updated
NEWS	12	DEC 14	GBFULL and FRFULL enhanced with IPC 8 features and functionality
NEWS	13	DEC 18	CA/Capplus pre-1967 chemical substance index entries enhanced with preparation role
NEWS	14	DEC 18	CA/Capplus patent kind codes updated
NEWS	15	DEC 18	MARPAT to CA/Capplus accession number crossover limit increased to 50,000
NEWS	16	DEC 18	MEDLINE updated in preparation for 2007 reload
NEWS	17	DEC 27	CA/Capplus enhanced with more pre-1907 records
NEWS	18	JAN 08	CHEMLIST enhanced with New Zealand Inventory of Chemicals
NEWS	19	JAN 16	CA/Capplus Company Name Thesaurus enhanced and reloaded
NEWS	20	JAN 16	IPC version 2007.01 thesaurus available on STN
NEWS	21	JAN 16	WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data
NEWS	22	JAN 22	CA/Capplus updated with revised CAS roles
NEWS	23	JAN 22	CA/Capplus enhanced with patent applications from India
NEWS	24	JAN 29	PHAR reloaded with new search and display fields
NEWS	25	JAN 29	CAS Registry Number crossover limit increased to 300,000 in multiple databases
NEWS	26	FEB 13	CASREACT coverage to be extended
NEWS	27	Feb 15	PATDPASPC enhanced with Drug Approval numbers
NEWS	28	Feb 15	RUSSIAPAT enhanced with pre-1994 records

NEWS EXPRESS NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8
NEWS X25	X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer

```

chain nodes :
18 19 20 21 22 29 30
ring nodes :
1 2 3 4 6 7 8 9 10 11 12 13 14 15 16 17 23 24 25 26 27 28
ring/chain nodes :
5
chain bonds :
1-6 3-20 4-12 9-19 15-18 20-21 21-22 22-23 22-30 26-29
ring/chain bonds :
2-5
ring bonds :
1-2 1-4 2-3 3-4 6-7 6-11 7-8 8-9 9-10 10-11 12-13 12-17 13-14 14-15
15-16 16-17 23-24 23-28 24-25 25-26 26-27 27-28
exact/norm bonds :
1-2 1-4 1-6 2-3 2-5 3-4 15-18 22-30
exact bonds :
3-20 4-12 9-19 20-21 21-22 22-23 26-29
normalized bonds :
6-7 6-11 7-8 8-9 9-10 10-11 12-13 12-17 13-14 14-15 15-16 16-17 23-24
23-28 24-25 25-26 26-27 27-28

```

```

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:CLASS 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:CLASS 19:CLASS
20:CLASS 21:CLASS 22:CLASS 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom
29:CLASS 30:CLASS

```

Stereo Bonds:

```

12-4 (Single Wedge).
20-3 (Single Hash).
30-22 (Single Wedge).

```

Stereo Chiral Centers:

```

3      (Parity=Even)
4      (Parity=Even)
22     (Parity=Even)

```

Stereo RSS Sets:


```
Type=Relative (Default). 3 Nodes= 3 4 22
```

```
L1      STRUCTURE UPLOADED
```

```
=> d l1
```

```
L1 HAS NO ANSWERS
```

```
L1      STR
```



Structure attributes must be viewed using STN Express query preparation.

=> s l1 exa sam

SAMPLE SEARCH INITIATED 12:11:30 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 1 TO ITERATE

100.0% PROCESSED 1 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**

PROJECTED ITERATIONS: 1 TO 80

PROJECTED ANSWERS: 0 TO 0

L2 0 SEA EXA SAM L1

=> s l1 exa full

FULL SEARCH INITIATED 12:11:50 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 10 TO ITERATE

100.0% PROCESSED 10 ITERATIONS

4 ANSWERS

SEARCH TIME: 00.00.01

L3 4 SEA EXA FUL L1


=> d scan

L3 4 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN

IN 2-Azetidinone, 1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl-14C6)-, (3R,4S)- (9CI)

MF C24 H21 F2 N O3


Absolute stereochemistry.



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 4 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN 2-Azetidinone, 1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl-13C6)-, (3R,4S)- (9CI)
 MF C24 H21 F2 N O3


Absolute stereochemistry.



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 4 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN 2-Azetidinone, 1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-, (3R,4S)- (9CI)
 MF C24 H21 F2 N O3
 CI COM

Absolute stereochemistry. Rotation (-).




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 4 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN 2-Azetidinone, 1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-, labeled with carbon-14, (3R,4S)-(9CI)
 MF C24 H21 F2 N O3

Absolute stereochemistry.



ALL ANSWERS HAVE BEEN SCANNED

=> file caplus biosis embase medline
 COST IN U.S. DOLLARS

SINCE FILE ENTRY	TOTAL SESSION
60.50	60.71

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 12:13:49 ON 22 FEB 2007
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 12:13:49 ON 22 FEB 2007
 Copyright (c) 2007 The Thomson Corporation

FILE 'EMBASE' ENTERED AT 12:13:49 ON 22 FEB 2007
 Copyright (c) 2007 Elsevier B.V. All rights reserved.

FILE 'MEDLINE' ENTERED AT 12:13:49 ON 22 FEB 2007

=> s 13

L4 2296 L3

Last Updated on STN: 1 Jul 2004

AB The benefits of lipid-lowering therapy in significantly reducing cardiovascular events has been established in many at-risk populations. However, patients with the metabolic syndrome (MS) pose a challenge for clinical management. A high degree of residual risk exists in patients with the MS or diabetes mellitus, and this is of growing importance because of the increasing prevalence of obesity and its associated comorbidities in the world. As the MS has emerged as a major risk factor for both cardiovascular disease and diabetes, targeting treatment to achieve aggressive goals becomes paramount. This article reviews emerging therapeutic strategies for the management of dyslipidemia in patients with the MS. .COPYRG. 2004 by Excerpta Medica, Inc.

=> d his

(FILE 'HOME' ENTERED AT 12:09:54 ON 22 FEB 2007)

FILE 'REGISTRY' ENTERED AT 12:10:22 ON 22 FEB 2007

L1 STRUCTURE UPLOADED
L2 0 S L1 EXA SAM
L3 4 S L1 EXA FULL

FILE 'CAPLUS, BIOSIS, EMBASE, MEDLINE' ENTERED AT 12:13:49 ON 22 FEB 2007

L4 2296 S L3
L5 1708 DUPLICATE REMOVE L4 (588 DUPLICATES REMOVED)
L6 1708 DUPLICATE REMOVE L4 CAPLUS (588 DUPLICATES REMOVED)
L7 2 S L6 AND (AUTOIMMUNE WITH DISORDER)
L8 25 S L6 AND ((MULTIPLE WITH SCLEROSIS) OR MS)

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	95.85	156.56
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-14.82	-14.82

STN INTERNATIONAL LOGOFF AT 12:20:00 ON 22 FEB 2007